The authors reply
Autors principals: | Chapman, D, Judge, PK, Arnold, T, Staplin, N, Clark, S, Haynes, R, Moffat, S, Herrington, WG, Hill, M |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
Elsevier
2023
|
Ítems similars
-
Sacubitril/valsartan in peritoneal dialysis—lessons from a pharmacokinetic study
per: Judge, PK, et al.
Publicat: (2023) -
Allocated but not treated: the silent 16% – Authors' reply
per: Horby, P, et al.
Publicat: (2022) -
Authors' reply
per: Herrington, W, et al.
Publicat: (2018) -
Impact of primary kidney disease on the effects of empagliflozin in patients with CKD
per: Judge, PK, et al.
Publicat: (2023) -
The prevention and management of chronic kidney disease among patients with metabolic syndrome
per: Zhu, D, et al.
Publicat: (2025)